Lung Cancer |

Is There Any Decisive Factor for Nephrotoxicity Due to the Treatment of Lung Cancer? Analysis of 104 Cases FREE TO VIEW

Makbule Ozlem Akbay, MD; Dilek Ernam, MD; Erhan Ogur, MD; Nuray Erdal, MD; Nilgün Hatabay, MD
Author and Funding Information

Sureyyapasa Chest Disease and Chest Surgery Center, Istanbul, Turkey

Chest. 2014;145(3_MeetingAbstracts):324A. doi:10.1378/chest.1834673
Text Size: A A A
Published online


SESSION TITLE: Lung Cancer Posters II

SESSION TYPE: Poster Presentations

PRESENTED ON: Saturday, March 22, 2014 at 01:15 PM - 02:15 PM

PURPOSE: Nephrotoxicity remains major complication of drugs that are used to treat malignant disease. The most common drugs that cause nephrotoxicity are antimetobolites, alkylating agents and anthracyclins. Chemotherapeutic agents can affect the kidney with clinical manifestations that range from an asymptomatic elevation of serum creatinine to acute renal failure requiring dialysis. Our aim is to investigate the presence of predictive factors in the development of nephrotoxicity in patients receiving chemotherapy.

METHODS: In this retrospective study, the clinical records of 104 newly diagnosed and previously untreated primary lung cancer patients admitted to the hospital, between september 2012-June 2013 were reviewed. We compared the demographic, haematologic and biochemical parameters of the patients who had or had not nephrotoxicity.

RESULTS: The patients included 93 men and 11 women with a median (range) age of 62 (37-82) years. Clinical stages were classified in the follwing manner, stage IV 59.6%, stage IIB 13.4%, stageIIIA 11.5%, stageIIB 3%, stage IIA 12.5% . In the study, adverse effects were seen in 45.2 % (n=47) of patients. Nephrotoxicity was seen in 20.2% (n=21) of cases. Other common adverse effects were anemia (24%,n=25) and neutropenia (16.3% n=17). There was no statistically significant difference found between the age and nephrotoxicity (p>0.05). Haematological and biochemical parameters showed no significant difference between patients with nephrotoxicity or not (p>0.05). Additionally, no significant difference was found between chemotherapy protocols (p>0.05). However, body surface area was found significantly higher in cases with nephrotoxicity (p<0.05).

CONCLUSIONS: In our study, we found that age and laboratory findings were not the predictive factor for nephrotoxicity. Besides we found an increased risk of nephrotoxicity with increasing body surface area. As a conclusion ,we believe that cumulative doses of chemotherapeutics should be taken into account in terms of nephrotoxicity.

CLINICAL IMPLICATIONS: Clinicians should be aware of nephrotoxicity in patients who has an higher body surface area because of cumulative doses of chemotherapeutics increase the risk.

DISCLOSURE: The following authors have nothing to disclose: Makbule Ozlem Akbay, Dilek Ernam, Erhan Ogur, Nuray Erdal, Nilgün Hatabay

No Product/Research Disclosure Information




Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Find Similar Articles
CHEST Journal Articles
PubMed Articles
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543